[Design strategies and analysis techniques for real-world cancer research] [0.03%]
[面向现实世界的癌症研究的设计策略与分析技术]
J J Peng,H K Tu
J J Peng
With the development of precision medicine and big data technology, a large amount of medical data continues to accumulate, providing solid support for the application of real world study (RWS) in the field of cancer. Real world data (RWD) ...
[Expert consensus on clinical application of whole nutritional oncology foods for special medical purposes (2025 edition)] [0.03%]
特殊医学用途全营养肿瘤配方食品临床应用专家共识（2025版）
Specialised Committee on Tumour Nutrition Therapy of Chinese Society of Clinical Oncology;Nutrition Oncology Branch of Chinese Nutrition Society
Specialised Committee on Tumour Nutrition Therapy of Chinese Society of Clinical Oncology;Nutrition Oncology Branch of Chinese Nutrition Society
Malnutrition and metabolic disorders occur in a high proportion of oncology patients, and malnutrition has a significant impact on both treatment and prognosis, resulting in a heavy disease and economic burden. In recent years, as awareness...
[Expert consensus on amivantamab clinical application and adverse reaction management (2025 edition)] [0.03%]
阿美替尼临床应用专家共识(2025年版)
Amivantamab Clinical Application and Adverse Reaction Management Consensus Expert Group
Amivantamab Clinical Application and Adverse Reaction Management Consensus Expert Group
Amivantamab is the first fully humanized bispecific antibody approved for the treatment of non-small cell lung cancer (NSCLC) in the world. Amivantamab can block epidermal growth factor receptor (EGFR) pathway and mesenchymal-epithelial tra...
[Expert consensus on the management practice of CD19 CAR-T cell therapy for B-cell lymphoma in China (2025 edition)] [0.03%]
中国CD19 CAR-T细胞治疗B细胞淋巴瘤管理专家共识(2025版)
National Cancer Center;Lymphoma Expert Committee of National Cancer Quality Control Center
National Cancer Center;Lymphoma Expert Committee of National Cancer Quality Control Center
In recent years, the incidence of B-cell non-Hodgkin lymphoma (B-NHL) in China has shown a steady increase, accounting for approximately 85%-90% of all lymphomas. Although standard immunochemotherapy regimens such as R-CHOP have led to long...
[Clinical pathway and expert consensus on the diagnosis and treatment of bone metastases from lung cancer (2025 edition)] [0.03%]
[肺腺癌骨转移诊断治疗临床路径与专家共识（2025版）]
Chinese Society of Clinical Oncology Non-Small Cell Lung Cancer Professional Committee
Chinese Society of Clinical Oncology Non-Small Cell Lung Cancer Professional Committee
Bone metastasis from lung cancer is one of the common complications in patients with advanced lung cancer, which can lead to pathological fractures, spinal cord compression, bone surgery, bone radiotherapy, and other skeletal related events...
[Expert consensus on pathological diagnosis of lung cancer in county-level and prefectural medical institutions (2025 edition)] [0.03%]
县级和地市级医疗机构肺恶性肿瘤病理诊断专家共识(2025年版)
Lung Cancer Study Group of Tumor Pathology Committee of Chinese Anti-Cancer Association;Consensus Expert Group on Standardized Pathologic Diagnosis of Lung Cancer in City and County Hospitals
Lung Cancer Study Group of Tumor Pathology Committee of Chinese Anti-Cancer Association;Consensus Expert Group on Standardized Pathologic Diagnosis of Lung Cancer in City and County Hospitals
Lung cancer is the malignant tumor with the highest morbidity and mortality in China. Standardized pathological diagnosis of lung cancer is crucial for determining clinical strategy and evaluating prognosis. Currently, there are issues such...
[Application of internal mammary perforator as recipient vessels in immediate breast reconstruction using deep inferior epigastric perforator flaps in early breast cancer] [0.03%]
以内乳动脉穿支血管为受区血管的早期乳腺癌深下腹横行肌皮瓣即刻乳房重建术式临床应用解剖学研究
X T Xie,J R Song,D C Lin et al.
X T Xie et al.
Objective: To investigate the clinical application of internal mammary perforator (IMP) as recipient vessels in immediate breast reconstruction using deep inferior epigastric perforator (DIEP) flap. Methods: The clinical data of 10 patients...
[Camrelizumab combined with tegafur gimeracil oteracil potassium (S-1) and nab-paclitaxel for the treatment of initially unresectable cholangiocarcinoma] [0.03%]
卡瑞利珠单抗联合替吉奥和白蛋白结合型紫杉醇治疗不可切除胆管癌患者
X F Liao,W J Zhao,H Hu et al.
X F Liao et al.
Objective: To explore the safety and efficacy of camrelizumab combined with tegafur gimeracil oteracil potassium (S-1) and albumin-bound paclitaxel in the treatment of initially unresectable cholangiocarcinoma. Methods: From October 2022 to...
[Prognosis analysis and 21-gene recurrence score assay applied in hormone receptor positive T1-3N1M0 breast cancer patients] [0.03%]
[激素受体阳性T1-3N1M0期乳腺癌患者的预后分析和21基因复发评分检测的应用价值]
Y N Zhang,Y Qu,F Mao et al.
Y N Zhang et al.
Objective: To explore the association of 21-gene recurrence score (RS) and clinicopathologic characteristics of hormone receptor (HR) positive T1-3N1M0 breast cancer and its value in prognosis evaluation. Methods: The clinicopathological da...
[The correlations between clinical characteristics including lesion site of papillary thyroid carcinoma and cervical lymph node metastasis] [0.03%]
[乳头状甲状腺癌临床特征包括病灶部位与颈淋巴结转移相关性分析]
J Ju,J R Li,J S Wang et al.
J Ju et al.
Objective: To investigate the correlations between primary location and other clinical characteristics of papillary thyroid carcinoma (PTC) with cervical lymph node metastasis, providing evidence for optimizing surgical strategies. Methods:...